FDAsafety guidance72% confidence
Cancer Clinical Trial Eligibility Criteria: Performance Status
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to AstraZeneca.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · Combination Therapy
- Sub-indication
- General
Related signal: Phase Ib/II Trial of Olaparib with AZD2014 or AZD5363 in Recurrent Endometrial and Ovarian Cancer